A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
UMC Utrecht
Olivia Newton-John Cancer Research Institute
City of Hope Medical Center
Mayo Clinic
University of California, San Francisco
National Cancer Institute, Naples
Corcept Therapeutics
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Arsenal Biosciences, Inc.
Marengo Therapeutics, Inc.
Izmir City Hospital
Tongji Hospital
National Institutes of Health Clinical Center (CC)
Karolinska Institutet
Universidad Autonoma de Madrid
Sorlandet Hospital HF
Peking Union Medical College Hospital
Mabwell (Shanghai) Bioscience Co., Ltd.
Sichuan Cancer Hospital and Research Institute
Xi'an Jiaotong University
Advaxis, Inc.
Mahidol University
Duke University
Kaiser Permanente
University of Florida
Sheba Medical Center
Rigshospitalet, Denmark
Clovis Oncology, Inc.
Hoosier Cancer Research Network
Catalysis SL
GamaMabs Pharma
Zhejiang Cancer Hospital
Women's College Hospital
Dana-Farber Cancer Institute
Medstar Health Research Institute
Jiangsu Cancer Institute & Hospital
Hoffmann-La Roche
Masonic Cancer Center, University of Minnesota
KU Leuven
McGill University Health Centre/Research Institute of the McGill University Health Centre
Wake Forest University Health Sciences
Huazhong University of Science and Technology
University of Michigan
Cedars-Sinai Medical Center
M.D. Anderson Cancer Center
Federal University of Minas Gerais
Stanford University